Mustang Bio, Inc. is committed to the development of novel CAR T immunotherapies and gene therapies in areas of unmet medical need. An integral part of achieving this goal is the conduct of robust and efficient clinical trials at the highest standards of quality attainable.
Information on Mustang Bio’s ongoing clinical trials in collaboration with its partners, including information for healthcare providers and patients interested in participating in any ongoing clinical trials, can be found at www.clinicaltrials.gov, or at the links for each specific trial:
MB-102 (CD123 CAR)
MB-106 (CD20 CAR)
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas